Alnylam Pharmaceuticals stock rating reiterated at Wells Fargo

Investing.com - Wells Fargo has maintained its Equal Weight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a price target of $395.00. The stock currently trades at $481.67, near its 52-week high of $492.62, after posting an impressive 105% gain over the past six months.

The research firm’s analyst team reaffirmed their neutral stance on the biopharmaceutical company, which specializes in RNA interference therapeutics. According to InvestingPro analysis, the company maintains a "Good" financial health score, though current valuations suggest the stock may be trading above its Fair Value.

Alnylam Pharmaceuticals develops treatments for genetic, cardio-metabolic, infectious, and central nervous system diseases.

The maintained price target of $395.00 represents the firm’s assessment of the stock’s fair value based on current market conditions and company fundamentals.

The Equal Weight rating suggests Wells Fargo analysts expect Alnylam’s stock to perform in line with the sector average over the next 12 months.

In other recent news, Alnylam Pharmaceuticals has reported strong first-quarter performance, driven by exceptional sales of Vutrisiran, a treatment for transthyretin-mediated amyloidosis (ATTR). Stifel responded to these results by raising its price target on Alnylam to $495, maintaining a Buy rating. Similarly, RBC Capital increased its price target to $500, citing impressive sales data for Amvuttra, another Alnylam product, which saw substantial growth since its cardiomyopathy launch. H.C. Wainwright also reaffirmed a Buy rating on Alnylam, highlighting potential benefits from recent FDA draft guidances that broaden clinical trial design flexibility.

In addition, Alnylam announced new analyses from its HELIOS-B Phase 3 study, showing that Vutrisiran significantly reduced gastrointestinal events in patients with ATTR-CM. However, the company faced regulatory scrutiny, leading to the withdrawal of a television commercial for its heart medicine Amvuttra. The FDA issued a warning letter claiming the ad was misleading, as it depicted patients engaging in activities like whale-watching and cheering at football games. These developments reflect a mix of positive sales and regulatory challenges for Alnylam Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.